| Ytd | -19.57% | |
| 1y | -36.18% |
| Open | 13.55 | Prev Close | 13.53 | Low | 13.41 | High | 13.81 | Mkt Cap | 6.76B |
| Vol | 5.83M | Avg Vol | 7.39M | EPS | 0.40 | P/E | 34.52 | Forward P/E | 5.64 |
| Beta | 0.23 | Short Ratio | 7.20 | Inst. Own | 99.32% | Dividend | 0.68 | Div Yield | 5.03 |
| Ex Div Date | 04-24 | Earning | 04-14 | 50-d Avg | 15.68 | 200-d Avg | 17.11 | 1yr Est | 20.44 |
JP Morgan analyst Thomas Palmer maintains Albertsons Companies (NYSE:ACI) with a Overweight and l
AC Immune Reports Interim 12-Month Data from Phase 1b/2 ABATE Trial of ACI-24 in Prodromal Alzheimer
For investors looking to build a defensive hedge within a diversified portfolio, these attractively
Citigroup analyst Paul Lejuez maintains Albertsons Companies (NYSE:ACI) with a Buy and lowers the
Wells Fargo analyst Edward Kelly maintains Albertsons Companies (NYSE:ACI) with a Overweight and
Albertsons has launched a new integration with commerce intelligence platform Criteo. The partnershi